J. Richardson

发表

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

Paul H. Bessette, A. Yang, O. Vasiljeva, 2013, Science Translational Medicine.

A small region of the ecotropic murine leukemia virus (MuLV) gag gene profoundly influences the types of polytropic MuLVs generated in mice

L. Evans, M. Lavignon, J. Richardson, 1997, Journal of virology.

Model‐Informed Drug Development of the Masked Anti‑PD‑L1 Antibody CX‐072

J. Burke, W. Kavanaugh, Michelle L. Green, 2020, Clinical pharmacology and therapeutics.

Variable immortalizing potential and frequent virus latency in blood-derived T-cell clones infected with human T-cell leukemia virus type I.

D. Hafler, P. Höllsberg, A. Lever, 1997, Blood.

Shared Usage of the Chemokine Receptor CXCR4 by Primary and Laboratory-Adapted Strains of Feline Immunodeficiency Virus

J. Schneider-Mergener, N. Heveker, T. Leste-Lasserre, 1999, Journal of Virology.

Lymphoid activation: a confounding factor in AIDS vaccine development?

T. Leste-Lasserre, A. Moraillon, G. Pancino, 2002, The Journal of general virology.

Different abilities of Friend murine leukemia virus (MuLV) and Moloney MuLV to induce promonocytic leukemia are due to determinants in both psi-gag-PR and env regions

M. Sitbon, R. Mukhopadhyaya, A. Corbin, 1994, Journal of virology.

Sequences responsible for the distinctive hemolytic potentials of Friend and Moloney murine leukemia viruses are dispersed but confined to the psi-gag-PR region

M. Sitbon, A. Corbin, J. Richardson, 1993, Journal of virology.

Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate

O. Vasiljeva, M. Belvin, W. Kavanaugh, 2022, Molecular cancer therapeutics.

Chromosomal positioning of human T-lymphotropic type 1 proviruses by fluorescence in situ hybridisation.

M. Ferguson-Smith, N. Rose, A. Lever, 2001, Journal of virological methods.

Virus inactivation in a proportion of human T-cell leukaemia virus type I-infected T-cell clones arises through naturally occurring mutations.

N. Rose, U. Desselberger, A. Lever, 2000, The Journal of general virology.

Evaluation of live feline immunodeficiency virus vaccines with modified antigenic properties.

A. Moraillon, P. Sonigo, J. Richardson, 2005, The Journal of general virology.

Use of PCR to Investigate the Cellular Tropism of Human T Cell Leukemia Virus Type 1

P. Rudge, A. Dalgleish, J. Cruickshank, 1991 .

Helper virus-free transfer of human immunodeficiency virus type 1 vectors.

A. Lever, J. Richardson, J. Kaye, 1995, The Journal of general virology.

In vivo cellular tropism of human T-cell leukemia virus type 1

P Rudge, P. Rudge, A. Dalgleish, 1990, Journal of virology.

Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope

A. Moraillon, G. Pancino, P. Sonigo, 1997, Journal of virology.

Delayed Infection after Immunization with a Peptide from the Transmembrane Glycoprotein of the Feline Immunodeficiency Virus

A. Moraillon, G. Pancino, J. Richardson, 1998, Journal of Virology.

Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents

O. Vasiljeva, M. Belvin, W. Kavanaugh, 2021, Cancer Immunology Research.

Regional specificity of HTLV-I proviral integration in the human genome.

G. Bernardi, A. Lever, D. Hafler, 1994, Gene.

CaMV gene expression : the analysis of two CaMV promoters in yeast and higher plants

J. Richardson, 1988 .

Packaging of human immunodeficiency virus type 1 RNA requires cis-acting sequences outside the 5' leader region

A. Lever, J. Richardson, L. Child, 1993, Journal of virology.

Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy.

S. Chen, W. Marasco, U. Ramstedt, 1998, Human gene therapy.

cis-acting sequences involved in human immunodeficiency virus type 1 RNA packaging

A. Lever, J. Richardson, J. Kaye, 1995, Journal of virology.

Natural antisense transcripts are detected in different cell lines and tissues of cats infected with feline immunodeficiency virus.

C. Vaquero, S Briquet, J Richardson, 2001, Gene.

Intracellular antibodies: development and therapeutic potential.

W. Marasco, J. Richardson, Jennifer Richardson, 1995, Trends in biotechnology.

T-cell activation by autologous human T-cell leukemia virus type I-infected T-cell clones.

D. Hafler, K. Wucherpfennig, P. Höllsberg, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Neutralization sensitivity and accessibility of continuous B cell epitopes of the feline immunodeficiency virus envelope.

A. Moraillon, G. Pancino, P. Sonigo, 1996, The Journal of general virology.

Comparison of serological tests for the diagnosis of feline immunodeficiency virus infection of cats.

A. Strosberg, A. Moraillon, G. Pancino, 1995, Veterinary microbiology.

Phenotypic Knockout of the Human Interleukin-2 Receptor α Chain on Primary and HTLV-I Transformed T Cells

W. Marasco, J. Richardson, 1998 .

Abstract 2664: An anti-Jagged-1/-2 Probody demonstrates inhibition of Jagged-dependent Notch signaling and is activated in multiple types of tumors

O. Vasiljeva, H. Lowman, L. Desnoyers, 2014 .

Abstract 2665: Transforming Notch ligands into tumor-antigen targets: A Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2

O. Vasiljeva, H. Lowman, L. Desnoyers, 2014 .

Abstract 4570: Development of a proteolytically activatable EGFR Probody for cancer therapy.

A. Yang, O. Vasiljeva, D. Hostetter, 2013 .

Human retroviruses: human T-cell leukaemia lymphoma virus (HTLV-I) and disease

A. Dalgleish, J. Cruickshank, J. Richardson, 1989 .

Preliminary clinical pharmacokinetics and dose-response to support a phase II dose selection for CX-2009: A masked probody drug conjugate to CD166.

A. Peterson, M. Stroh, J. Frye, 2020 .

A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity

O. Vasiljeva, M. Belvin, W. Kavanaugh, 2022, Cancer research.

Abstract A164: EGFR-CD3 bispecific Probody™ therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies

W. Kavanaugh, B. Irving, Yuanhui Huang, 2018 .

Abstract 2975: Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas

W. Kavanaugh, J. Terrett, Yuanhui Huang, 2016 .

Abstract A203: CD3-EGFR bispecific Probody™ therapeutics induced tumor regressions and increased therapeutic window in preclinical studies

W. Kavanaugh, D. Hostetter, B. Irving, 2015 .

Inducible knockout of the interleukin-2 receptor alpha chain: expression of the high-affinity IL-2 receptor is not required for the in vitro growth of HTLV-I-transformed cell lines.

T. Waldmann, J. Sodroski, W. Marasco, 1997, Virology.

Abstract A081: A PD-L1-targeted Probody provides antitumor efficacy while minimizing induction of systemic autoimmunity

M. Kavanaugh, O. Vasiljeva, B. Irving, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.